Efficacy and Safety of Total Body Irradiation versus Chemotherapy Conditioning for Hematopoietic Stem Cell Transplant in Adult Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis

Hasaan Ans<sup>1</sup>, Haiqah Amjad<sup>2</sup>, Sara Nazir<sup>3</sup>, Sara Sajjad Cheema<sup>4</sup>, Dhruv Mistry<sup>5</sup>, Tazeen Fatima<sup>6</sup>, Ahmed Yar Khan<sup>7</sup>, Muhammad Usama Imtiaz<sup>3</sup>, Fasih Mand Khan<sup>1</sup>, Saif Khalid<sup>8</sup>, Mohammad Ebad Ur Rehman<sup>9</sup>, Muhammad Salman Faisal<sup>10</sup>

- <sup>1.</sup> Department of Medicine, FMH College of Medicine and Dentistry, Lahore, Pakistan
- Department of Medicine, Stockport NHS Foundation Trust, Manchester, United Kingdom
- 3. Department of Medicine, Jinnah Hospital, Lahore, Pakistan
- <sup>4.</sup> Department of Medicine, Lahore Medical and Dental College, Lahore, Pakistan
- 5. Department of Medicine, Mahatma Gandhi Institute of Medical Sciences, Wardha, India
- 6. Department of Medicine, Jinnah Medical and Dental College, Karachi, Pakistan
- Department of Stroke Medicine, University Hospitals Coventry and Warwickshire NHS Trust of Medicine, Coventry, United Kingdom
- 8. Department of Medicine, Royal College of Surgeons, Dublin, Ireland
- 9. Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan
- <sup>10.</sup> Department of Hematology-Oncology, University of Oklahoma, United States

#### **Corresponding Authors:**

1) Mohammad Ebad Ur Rehman; <a href="mailto:ebadrehman.rehman@gmail.com">ebadrehman.rehman@gmail.com</a>

**Keywords:** acute lymphoblastic leukemia; total body irradiation; chemotherapy; hematopoietic stem cell transplant

#### **Abstract**

## **Background**

Hematopoietic stem cell transplantation (HSCT) is a potentially curative option for adults with acute lymphoblastic leukemia (ALL) who have achieved remission. This systematic review and meta-analysis compare the efficacy of total body irradiation (TBI) versus chemotherapy (CHT) based regimens for conditioning in adult ALL patients being prepared for HSCT.

#### Methods

A comprehensive literature search was conducted in MEDLINE, Embase, the Cochrane Library, and relevant trial registries from their inception to August 2024. The inclusion criteria encompassed all randomized controlled trials (RCTs) and cohort studies that compared TBI) with CHT as conditioning regimens prior to HSCT in adult patients with ALL. The primary outcomes assessed were overall survival (OS) and event-free survival (EFS). All statistical analyses were carried out using RevMan version 5.4, using a random-effects model.

#### **Results**

This meta-analysis includes 20 cohort studies and one RCT. The relative risk (RR) for OS was 1.37 (95% CI: 1.20–1.57), while the RR for EFS was 1.28 (95% CI: 1.15–1.43), highlighting the superior efficacy of TBI-based regimens in this patient population. TBI was also superior in terms of relapse rate (RR 0.71). The two regimens were comparable in terms of non-relapse mortality, acute graft-versus-host disease (GVHD), and chronic GVHD.

#### **Conclusion**

When used for conditioning prior to HSCT, TBI-based conditioning regimens demonstrate superior OS, EFS, and relapse outcomes compared to CHT-based regimens.

#### Introduction

Acute lymphoblastic leukemia (ALL), a malignant disorder involving lymphoid progenitor cells, manifests in both pediatric and adult populations, with the highest incidence observed between 2 and 5 years of age<sup>1</sup>. Significant progress in treatment development has achieved cure rates above 80% in children. The use of risk-based stratification and enhanced chemotherapy protocols has greatly improved survival rates in those with ALL, especially in pediatric patients (ages 1-14) and also in adolescents and young adults (ages 15-39). Despite these advances, outcomes for older adults ( $\geq$ 40 years) and those with relapsed or refractory ALL remain unsatisfactory<sup>1,2</sup>. Standard management of ALL typically involves a combination of chemotherapy administered in phases of induction, consolidation, and maintenance spanning 2.5 to 3 years. This regimen also includes prophylactic measures for the central nervous system (CNS) and may incorporate allogeneic stem cell transplantation (ASCT) during initial or subsequent remissions<sup>3</sup>. Transplantation, compared to standard methods, may lead to improved disease-free survival rates. However, the success of this approach is significantly influenced by patient selection criteria. It is recommended for pediatric patients with ALL who have relapsed or are at high risk of relapse during their first complete remission, as well as for patients who fail to achieve MDR negativity, have not received intensive induction therapy, or exhibit high-risk cytogenetic and molecular characteristics<sup>4–6</sup>.

In patients with ALL, prior to allogeneic and autologous hematopoietic stem cell transplantation (HSCT), total body irradiation (TBI) is administered as part of the conditioning regimen, delivering a relatively homogeneous dose of radiation to the entire body. TBI functions in two capacities: it is both cytotoxic and immunosuppressive. This eliminates the remaining disease and creates space in the bone marrow, weakening the immune system to prevent rejection of

transplanted donor cells<sup>7</sup>. There is ongoing debate over whether chemotherapy (CHT) or TBI is more effective as part of conditioning regimens for patients undergoing HSCT. TBI has certain advantages over chemotherapy, such as greater tumor cytotoxicity and the ability to penetrate tissues more effectively. Since its administration does not rely on blood flow or physiological barriers like renal or hepatic function, TBI can reach "sanctuary" regions, including the CNS, testes, and orbits, which may be less accessible to CHT<sup>7</sup>.

Several meta-analyses have evaluated TBI versus CHT-based conditioning before HSCT in adults with ALL, with promising results showing a statistically significant reduction in side effects and an improvement in overall survival (OS). However, new studies have since been published. A pooled analysis could provide further insight into critical outcomes such as graft-versus-host disease (GVHD), relapse, mortality, and event-free survival (EFS). Therefore, we have conducted a systematic review and meta-analysis to compare outcomes between TBI and CHT conditioning in the adult ALL population.

## Methods

Our meta-analysis was performed following the guidelines outlined in the Cochrane Handbook for Systematic Reviews of Interventions, and the results are reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement<sup>8,9</sup>. Our protocol is registered with PROSPERO, the International Prospective Register of Systematic Reviews.

#### **Data sources and Searches**

We conducted an electronic search of the Cochrane Central Register of Controlled Trials (CENTRAL, via the Cochrane Library), MEDLINE, Embase (Elsevier), and ClinicalTrials.gov from their inception through August 2024 using a comprehensive search strategy. MeSH terms and keywords for "Whole Body Irradiation" and "Precursor Cell Lymphoblastic Leukemia-Lymphoma" were included. Additionally, we reviewed reference lists of included studies and related systematic reviews to identify other relevant studies. Detailed search strategy for Pubmed (MEDLINE) is reported in Supplementary Table 1.

## **Eligibility Criteria**

The inclusion criteria were: (1) population: adult patients with ALL, (2) intervention: TBI-based regimens, (3) comparison: CHT-based regimens, and (4) study design: RCTs or cohort studies. The exclusion criteria were: (1) any study designs other than RCTs and cohort studies and (2) studies involving animals or minors.

# **Study Selection and Data Abstraction**

We imported all studies identified through our online search into Rayan and removed duplicates. Two authors (H.A. and D.M.) independently screened the titles and abstracts, excluding irrelevant articles. We then conducted a full-text review of the remaining studies and finalized those that met our eligibility criteria. A third author (M.E.U.R.) resolved any disagreements during the study selection process.

Two review authors (H.A. and M.U.I.) extracted data from the included studies using a prepiloted data extraction form into an Excel spreadsheet. Data pertaining to author name, year of publication, study setting, study design, sample size, age, ALL subtype, remission status, stem cell source, dose, frequency an duration of TBI and CHT regimens used were extracted. The extracted data were compared, and any discrepancies were addressed through discussion with a

third author (M.E.U.R.).

**Outcome Measures** 

The primary outcome measures were OS and EFS. The secondary outcome measures were

relapse, non-relapse mortality (NRM), acute graft versus host disease (aGVHD), acute graft

versus host disease grade 3 and 4 (aGVHD 3-4) and chronic graft versus host disease (cGVHD).

**Risk of Bias Assessment** 

Two independent investigators (S.N. and A.Y.A.) assessed the quality of the included RCT and

cohort studies using the Revised Cochrane Risk of Bias tool (RoB 2.0) and the Newcastle-

Ottawa Scale (NOS), respectively. Any discrepancies were resolved by a senior investigator

 $(M.E.U.R.)^{10,11}$ .

**Data Synthesis** 

Review Manager (RevMan, Version 5.4) performed the meta-analyses. Risk ratios (RRs) and

corresponding 95% confidence intervals (CIs) for both primary and secondary outcomes were

extracted from each study. A random-effects model with the Mantel-Hanszel method was

employed for the meta-analyses. Statistical heterogeneity was assessed using the Higgins I<sup>2</sup>

statistic.

**Results** 

**Search Results** 

The initial search garnered 1,012 articles. Title and abstract screening resulted in the exclusion

of 854 articles, and 61 out of the remaining 82 studies were excluded after full-text

screening. Finally, 21 articles were included in this meta-analysis. The detailed screening

process is depicted in Figure 1.

**Study Characteristics** 

A total of 21 studies were included in this meta-analysis 12-32. The studies comprised eleven

cohort studies and one RCT. Sample sizes ranged from 95 to 2,780 patients, with a cumulative

total of 12,046 participants. Conditioning regimens were TBI-based, typically combined with

etoposide or cyclophosphamide, or CHT-based regimens, which commonly included busulfan,

fludarabine, and cytarabine. Detailed study characteristics, including sample sizes, patient

demographics, and conditioning protocols, are provided in Table 1.

Risk of Bias in Included Studies

The quality assessment of the included studies is presented in Supplementary Figure 1 and

Supplementary Table 2. The RCT by Zhang et al. demonstrated a low risk of bias across all

domains. Out of the twenty observational studies, five had a score of 9, seven had a score of 8,

six had a score of 7, and two had a score of 6.

**Synthesis of Primary Outcomes** 

**Overall Survival** 

The meta-analysis for OS included data from 18 studies. The pooled results favoured TBI over CHT, with a RR of 1.37 (95% CI: 1.20–1.57, p<0.00001,  $I^2 = 83\%$ ) (Figure 2).

# **Event-Free Survival**

EFS was analyzed across 17 studies. The pooled RR for EFS was 1.28 (95% CI: 1.15–1.43, p<0.00001,  $I^2=45\%$ ), indicating a significant improvement in event-free survival for patients treated with TBI compared to CHT (Figure 3).

#### Relapse

Relapse was reported in 17 studies. The pooled RR for relapse was 0.71 (95% CI: 0.62–0.80, p<0.00001,  $I^2=63\%$ ), indicating a statistically significant reduction in relapse risk for patients receiving TBI compared to those receiving CHT (Supplementary Figure 2).

#### **Non-Relapse Mortality**

NRM was evaluated in 17 studies. The pooled analysis showed no significant difference between TBI and CHT, with an RR of 0.86 (95% CI: 0.69–1.07, p = 0.17,  $I^2 = 69\%$ ) (Supplementary Figure 3).

## **Acute Graft-Versus-Host Disease**

The incidence of aGVHD was reported in 8 studies. The pooled RR was 1.02 (95% CI: 0.92–1.13), with no statistically significant difference between TBI and CHT (p = 0.68). Heterogeneity was low ( $I^2 = 19\%$ ) (Supplementary Figure 4). aGVHD grades 3–4 was analyzed in 8 studies.

The RR was 0.93 (95% CI: 0.66–1.31, p = 0.67,  $I^2 = 20\%$ ) with no significant difference between TBI and CHT (Supplementary Figure 5).

## **Chronic Graft-Versus-Host Disease**

cGVHD was reported in 10 studies. The pooled RR was 1.12 (95% CI: 0.95-1.31, p = 0.18,  $I^2 = 40\%$ ), indicating no significant difference between the two groups (Supplementary Figure 6).

# **Discussion**

Our meta-analysis, which included 20 cohort studies and 1 randomized controlled trial involving 12,046 patients, found that TBI as a conditioning regimen for ALL patients undergoing HSCT is associated with improved OS, EFS, and lower relapse rates than CHT-only myeloablative regimens. No significant differences were observed between the two regimens regarding NRM, aGVHD, aGVHD grades 3-4, or cGVHD.

Our findings show that TBI significantly enhances OS in ALL patients compared to CHT, with a relative risk (RR) of 1.37. EFS was also better with TBI, with an RR of 1.28. These results are consistent with prior research. For example, Khimani et al. analyzed eight observational, non-randomized retrospective studies involving 5,328 patients and reported that TBI-based regimens were associated with improved EFS compared to CHT-only regimens, with hazard ratios (HR) of 0.76 (p=0.002) and 0.74 (p=0.003)<sup>33</sup>. Similarly, Rehman et al. reviewed data from 15 studies with 5,629 pediatric patients and found that TBI-based regimens led to better OS and EFS, with relative risks (RR) of 1.21 and 1.34, respectively<sup>6</sup>. Eroglu et al. compared 95 patients undergoing HSCT with TBI plus cyclophosphamide (TBI + Cy) versus busulfan plus cyclophosphamide (Bu + Cy) and found that the median OS was 37 months for the TBI + Cy group compared to 12

months for the Bu + Cy group (p=0.003), with median EFS of 13 months versus 4 months (p=0.006), indicating a significant advantage for the TBI + Cy regimen<sup>34</sup>. Collectively, these studies support our conclusion that TBI-based conditioning is more effective than chemotherapy in adult ALL patients undergoing HSCT. In contrast, a retrospective study by Abdeljelil et al., involving 95 patients with 61 receiving TBI-based regimens and 34 receiving chemotherapies, found that TBI-based regimens were associated with better OS and EFS (52% vs. 42.6% and 49% vs. 34.6%, respectively). However, these results were not statistically significant, with p-values of 0.2 for both OS and EFS, likely due to the small sample size<sup>12</sup>.

Cytogenetic abnormalities are independent prognostic factors in ALL. The most important chromosomal abnormality in ALL is the Philadelphia chromosome (Ph), characterized by the balanced translocation t(9;22) (q34;q11). Other major cytogenetic abnormalities include t(4;11) (q21;q23) involving the MLL gene, translocations such as t(8;14), t(1;19), and t(10;14), and structural abnormalities such as 9p, 6q, and  $12p^{35}$ . Ph can also be detected by the polymerase chain reaction for the BCR-ABL fusion protein and is present in 20% to 30% of adults with ALL<sup>35</sup>. Ph positivity confers a uniformly poor prognosis with standard chemotherapy. The initial white blood cell (WBC) count at diagnosis is an important prognostic factor reported in every study of ALL<sup>35</sup>. An arbitrary cutoff of  $30 \times 10^{49}$  WBCs/L for B-lineage ALL or  $100 \times 10^{49}$  WBCs/L for T-lineage ALL has often been used in clinical studies. Understanding these mechanisms underscores the need for effective conditioning regimens and targeted therapies in ALL treatments.

Our meta-analysis also found that the incidence of adverse events, including cGVHD, was comparable between TBI and chemotherapy regimens. Khimani et al. reported no significant

difference in cGVHD incidence between TBI-based and CHT-only regimens, with a risk ratio of 1.10 and a p-value of 0.63<sup>33</sup>. Similarly, Gooptu et al. found that the cumulative incidence of cGVHD was comparable between regimens, with a 2-year estimate of 55% for FluBu and 49% for CyTBI, and a p-value of 0.21<sup>36</sup>. Our study's finding of a decreased relapse rate with TBI, showing an RR of 0.71 and a p-value of 0.0003, aligns with previous research. Khimani et al. similarly reported a lower incidence of relapse with TBI-based regimens compared to chemotherapy-only regimens, with an RR of 0.82 and a p-value of 0.02<sup>33</sup>. Additionally, Elvira Mora et al's study, spanning from 2002 to 2018, compared 63 patients receiving TTB-based regimens with 114 patients receiving TBI-based regimens, finding a lower 5-year cumulative incidence of relapse in the TBI cohort (30%) compared to the TTB cohort (47%), with a p-value of 0.03<sup>37</sup>.

TBI offers several advantages when comparing TBI versus chemotherapy (CHT) as conditioning regimens for ALL patients before HSCT. The benefit of TBI is that it provides uniformity in the radiation dosage to the entire body and penetrates areas such as the central nervous system (CNS) and testes, which are barriers to chemotherapy. Chemotherapy, which uses agents like cyclophosphamide and busulfan to create DNA cross-links and induce cell death, may not provide the same comprehensive disease control as TBI. The effectiveness of chemotherapy can be inconsistent depending on the specific drugs and patient characteristics, potentially resulting in higher relapse rates. TBI delivers a high dose of ionizing radiation, causing widespread DNA damage and cell death in the hematopoietic system by inducing both single- and double-strand breaks in DNA. TBI is both myeloablative and immunosuppressive at high doses, but at lower doses, it is only immunosuppressive and not myeloablative. Non-myeloablative and reduced-intensity conditioning regimens use lower doses of TBI, focusing on immunosuppression only.

When TBI is combined with myeloablative conditioning regimens, it can be delivered before or after the chemotherapy, most often cyclophosphamide. The most common TBI schedules include twice-daily 2-Gy fractions given over 3 days (total dose 12 Gy); twice-daily 1.5-Gy fractions over 4-4.5 days (total dose 12-13.5 Gy); three-times-daily 1.2-Gy fractions over 4 days (total dose 12-13.2 Gy); and once-daily 3-Gy fractions for 4 days (total dose 12 Gy)<sup>38</sup>. The most common early side effects of TBI are fatigue and skin changes<sup>39</sup>. TBI has limited long-term complications in adults. Functional lung abnormalities are observed in 19% of cases, always without clinical effect. Clinical hypothyroidism is a very rare complication, and thyroid hormones are perturbed in 7% <sup>40</sup>. While chemotherapy might be less effective in disease control, it generally has fewer long-term complications than TBI.

This meta-analysis has several limitations. The retrospective studies introduce potential selection bias and variability in how patients were assigned to conditioning regimens. Differences in clinical practices, including TBI dosing and protocols, complicate the interpretation of results. The study also faces challenges due to inconsistent outcome definitions and incomplete long-term data on quality of life and post-transplant complications. Unmeasured confounders, such as genetic factors and previous treatments, may also influence the findings. The short follow-up period limits the assessment of long-term adverse effects. To address these issues, future research should focus on large-scale, prospective studies with standardized methodologies and extended follow-up to accurately evaluate and compare the efficacy and safety of TBI versus chemotherapy regimens.

In conclusion, our meta-analysis indicates that TBI as a conditioning regimen for ALL patients undergoing HSCT results in better OS, EFS, and reduced relapse rates compared to CHT-only

regimens. No significant differences were observed between TBI and chemotherapy regarding NRM, and acute or chronic GVHD. However, due to limitations such as variability in treatment protocols and a short follow-up period, further large-scale research is needed to confirm these findings and optimize conditioning strategies for ALL patients.

## **Statements and Declarations**

## **Financial support**

No financial support was received for this study.

#### **Conflicts of interest**

The authors report no relationships that could be construed as a conflict of interest.

## Acknowledgments

Not applicable.

#### Availability of data

The data supporting this study's findings are available from the corresponding author upon reasonable request.

#### References

- 1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. *Lancet Lond Engl.* 2008;371(9617):1030-1043. doi:10.1016/S0140-6736(08)60457-2
- 2. Malard F, Mohty M. Acute lymphoblastic leukaemia. *Lancet Lond Engl.* 2020;395(10230):1146-1162. doi:10.1016/S0140-6736(19)33018-1
- 3. Jabbour E, O'Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. *Cancer*. 2015;121(15):2517-2528. doi:10.1002/cncr.29383

- 4. Lazarus HM, Rowe JM. Bone marrow transplantation for acute lymphoblastic leukemia (ALL). *Med Oncol Northwood Lond Engl.* 1994;11(2):75-88. doi:10.1007/BF02988834
- 5. Saadeh SS, Litzow MR. Hematopoietic stem cell transplant in adults with acute lymphoblastic leukemia: the present state. *Expert Rev Hematol*. 2018;11(3):195-207. doi:10.1080/17474086.2018.1433030
- 6. Rehman MEU, Chattaraj A, Mahboob A, et al. Total Body Irradiation Versus Chemotherapy Conditioning in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis. *Clin Lymphoma Myeloma Leuk*. 2023;23(4):249-258. doi:10.1016/j.clml.2023.01.004
- 7. Sabloff M, Tisseverasinghe S, Babadagli ME, Samant R. Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on? *Curr Oncol Tor Ont.* 2021;28(1):903-917. doi:10.3390/curroncol28010089
- 8. Cochrane Handbook for Systematic Reviews of Interventions. Accessed July 5, 2024. https://training.cochrane.org/handbook
- 9. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:10.1136/bmj.n71
- 10. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:14898. doi:10.1136/bmj.14898
- 11. Ottawa Hospital Research Institute. Accessed July 5, 2024. https://www.ohri.ca/programs/clinical\_epidemiology/oxford.asp
- 12. Abdeljelil NB, Ouerghi R, Yaiche IB, et al. Total body irradiation-based conditioning versus chemotherapy before allogeneic stem cell transplantation for adults with acute lymphoblastic leukemia. *Clin Hematol Int*. 2024;6(3):4-8. doi:10.46989/001c.120991
- 13. Bazarbachi AH, Al Hamed R, Labopin M, et al. Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. *Bone Marrow Transplant*. 2020;55(3):595-602. doi:10.1038/s41409-019-0702-2
- 14. Cahu X, Labopin M, Giebel S, et al. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. *Bone Marrow Transplant*. 2016;51(3):351-357. doi:10.1038/bmt.2015.278
- 15. Dholaria B, Labopin M, Angelucci E, et al. Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. *Transplant Cell Ther*. 2021;27(2):171.e1-171.e8. doi:10.1016/j.jtct.2020.10.008
- 16. Eroglu C, Pala C, Kaynar L, et al. Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients

- with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant. *Leuk Lymphoma*. 2013;54(11):2474-2479. doi:10.3109/10428194.2013.779691
- 17. Greil C, Engelhardt M, Ihorst G, et al. Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia. *Bone Marrow Transplant*. 2021;56(4):841-852. doi:10.1038/s41409-020-01101-z
- 18. Harada K, Tachibana T, Ohashi K, et al. The effect of melphalan dose and total body irradiation as reduced-intensity conditioning for acute lymphoblastic leukemia patients undergoing allogeneic stem cell transplantation. *Leuk Lymphoma*. 2019;60(14):3521-3528. doi:10.1080/10428194.2019.1636986
- 19. Hirschbühl K, Labopin M, Polge E, et al. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years—a registry-based study by the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant*. 2023;58(8):874. doi:10.1038/s41409-023-01966-w
- 20. Kalaycio M, Bolwell B, Rybicki L, et al. BU- vs TBI-based conditioning for adult patients with ALL. *Bone Marrow Transplant*. 2011;46(11):1413-1417. doi:10.1038/bmt.2010.314
- 21. Kebriaei P, Anasetti C, Zhang MJ, et al. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. *Biol Blood Marrow Transplant*. 2018;24(4):726-733. doi:10.1016/j.bbmt.2017.11.025
- 22. Konuma T, Ooi J, Monna-Oiwa M, et al. Total body irradiation-based versus busulfan-based myeloablative conditioning for single-unit cord blood transplantation in adults. *Leuk Lymphoma*. 2022;63(5):1191-1201. doi:10.1080/10428194.2021.2018583
- 23. Mora E, Montoro J, Balaguer A, et al. Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia. *Bone Marrow Transplant*. 2024;59(8):1137-1145. doi:10.1038/s41409-024-02298-z
- 24. Mitsuhashi K, Kako S, Shigematsu A, et al. Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. *Biol Blood Marrow Transplant*. 2016;22(12):2194-2200. doi:10.1016/j.bbmt.2016.09.007
- 25. Niu J, Chen Z, Gao J, et al. Total Body Irradiation—Based Conditioning Regimen Improved the Survival of Adult Patients With T-Cell Lymphoblastic Lymphoma After Allogeneic Peripheral Blood Stem Cell Transplantation. *Cell Transplant*. 2022;31. doi:10.1177/09636897221108890
- 26. Pavlů J, Labopin M, Niittyvuopio R, et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. *J Hematol OncolJ Hematol Oncol*. 2019;12:108. doi:10.1186/s13045-019-0790-x

- 27. Park H, Byun JM, Koh Y, et al. Comparison of Different Conditioning Regimens in Allogeneic Hematopoietic Stem-Cell Transplantation Shows Superiority of Total Body Irradiation-Based Regimen for Younger Patients With Acute Leukemia: A Nationwide Study. *Clin Lymphoma Myeloma Leuk*. 2019;19(11):e605-e615. doi:10.1016/j.clml.2019.08.005
- 28. Sakellari I, Gavriilaki E, Chatziioannou K, et al. Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study. *Ann Hematol*. 2018;97(10):1987-1994. doi:10.1007/s00277-018-3383-9
- 29. Shen Y, Liu M, Shen D, et al. Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study. *Bone Marrow Transplant*. 2024;59(7):1037-1039. doi:10.1038/s41409-024-02280-9
- 30. Swoboda R, Labopin M, Giebel S, et al. Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant*. 2022;57(3):399-406. doi:10.1038/s41409-021-01550-0
- 31. Wang Y, Tien F, Tsai C, et al. Busulfan □ containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study. *Cancer Rep.* 2021;5(3):e1488. doi:10.1002/cnr2.1488
- 32. Zhang H, Fan Z, Huang F, et al. Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial. *J Clin Oncol*. 2023;41(2):343-353. doi:10.1200/JCO.22.00767
- 33. Khimani F, Dutta M, Faramand R, et al. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. *Transplant Cell Ther*. 2021;27(7):620.e1-620.e9. doi:10.1016/j.jtct.2021.03.026
- 34. Eroglu C, Pala C, Kaynar L, et al. Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant. *Leuk Lymphoma*. 2013;54(11):2474-2479. doi:10.3109/10428194.2013.779691
- 35. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. *Blood*. 2005;106(12):3760-3767. doi:10.1182/blood-2005-04-1623
- 36. Gooptu M, Kim HT, Ho VT, et al. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic

Stem Cell Transplantation in the Modern Era: A Cohort Analysis. *Biol Blood Marrow Transplant*. 2018;24(8):1733-1740. doi:10.1016/j.bbmt.2018.03.011

- 37. Mora E, Montoro J, Balaguer A, et al. Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia. *Bone Marrow Transplant*. 2024;59(8):1137-1145. doi:10.1038/s41409-024-02298-z
- 38. Wong JYC, Filippi AR, Dabaja BS, Yahalom J, Specht L. Total Body Irradiation: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). *Int J Radiat Oncol Biol Phys.* 2018;101(3):521-529. doi:10.1016/j.ijrobp.2018.04.071
- 39. Sharma SK. Total Body Irradiation. In: Sharma SK, ed. *Basics of Hematopoietic Stem Cell Transplant*. Springer Nature; 2023:231-235. doi:10.1007/978-981-19-5802-1\_19
- 40. Thomas O, Mahé MA, Campion L, et al. Long-term complications of total body irradiation in adults. *Int J Radiat Oncol Biol Phys.* 2001;49(1):125-131. doi:10.1016/S0360-3016(00)01373-0

# Figure Legend

Figure 1: PRISMA Flowchart

Figure 2: Forest Plot of Overall Survival

Figure 3: Forest Plot of Event-Free Survival

Table 1: Characteristics of Included Studies

Study ID	Settin g	Study Design	Sample Size	Mean Age, in years (S.D.)	ALL Subty pe (B- cell/T -cell)	Status (CR 1/	Stem Cell Source (BM/PS C/CB)	TBI Regimen	CHT Regimen
Abdelj elil 2024 Bazarb	Tunis ia Euro	Retrosp ective Cohort Retrosp	95 ( 61 vs 34 ) 115 (60	30 (18- 50)* 30	56/39	80/15	46/49/0	TBI 9.9 Gy + Etoposide (60 mg/kg per day)/Cyclopho sphamide (60 mg/kg per day)	Busulfan 3.2 mg/kg per day and Cyclophosp hamide 60mg/kg for two days (Bu-Cy) or Fludarabine 30 mg/m2 once a day for 6 days and Busulfan 3.2 mg/kg per day and Cyclophosp hamide 60mg/kg for two days (FBC) or Thiotepa 5 mg/kg once a day for 2 days and Busulfan 3.2 mg/kg per day and Cyclophosp hamide 60mg/kg for two days (FBC) or Thiotepa 5 mg/kg once a day for 2 days and Busulfan 3.2 mg/kg per day and Fludarabine 50 mg/m2 once a day for 3 days (TBF).
achi	pe	ective	vs 55)	(18-	35/34	0/115	NR	8 Gy	Busulfan


2020		Cohort		63)*					greater than 8 mg/kg or IV Bu greater than 6.4 mg/kg
Cahu 2015	Euro pe	Retrosp ective Cohort	601 ( 523 vs 78 )	30 ( 18-63 ) *	0/601	414/18	196/405/ 0	TBI and Cyclophospha mide	IV busulfan— cyclophosp hamide
Dholar ia 2021		Retrosp ective Cohort	427 ( 188 vs 239 )	31*	291/1 36	208/21 9	229/198/ 0	TBI and Fludarabine	thiotepa- busulfan- fludarabine
Eroglu 2013	Turk	Retrosp ective Cohort	95 ( 45 vs 50 )	25 (9– 54)*	NR	81/14	NR	TBI 12 Gy + Cyclophospha mide 60 mg/kg/day	Busulfan 3.2 mg/kg/day and Cyclophosp hamide 60 mg/kg/day
Greil 2020	Germ any	Retrosp ective Cohort	180 (119 vs 61)	37 (16– 76)*	50/44	38/41	27/153/0	TBI 12 Gy	NR
Harada 2019	Japan	Retrosp ective Cohort	507 (355 vs 152)	HDM/ TBI 57 (16– 69) / LDM/ TBI 61 (21– 71) vs HDM 58 (16– 67)*	417/2 7	388/72	237/72/1 98	TBI 2–4 Gy and Melphalan (20–140 mg/m2	Melphalan 120- 140mg/m2
Hirsch bühl 2023	Euro pe	Retrosp ective Cohort	501 (262 vs 239)	FluTB I8 56 (45.4– 76.1)/ FluBu 6.4 60.3 (45.1– 72)/	435/6 6	NR	32/469/0	TBI 8 Gy and Fludarabine	Fludarabine and busulfan 6.4/9.6 mg/kg

				FluBu 9.6 55.4 (45.9– 65.6)*					
Kalayc io 2010	USA	Retrosp ective Cohort	86 (35 vs 51)	40 (19- 56) vs 33 (19- 60)*	65/14	35/47	78/4/0	TBI 1200cGy + Etoposide 60 mg/kg	Busulfan 16 mg/kg, Cyclophosp hamide 120 mg/kg or Busulfan 16 mg/kg, Cyclophosp hamide 120 mg/kg, Etoposide 50mg/kg
									Busulfan 11.5 (9.8- 12.8) mg/kg and Clolarabine 160mg/m2, or Busulfan 11.5 (9.8- 12.8) mg/kg and Fludarabine 160 (159- 160) mg/m2, or Busulfan 11.5 (9.8- 12.8) mg/kg and Melphalan
Kebria ei 2018	USA	Retrosp ective Cohort	1118 (819 vs 299)	37 (18- 60) vs 38 (18- 60)*	924/1 94	833/28 5	244/874/ 0	TBI 9-12 Gy + Cyclophospha mide 106 (89.5 -119.5) mg/kg or TBI 13- 16Gy + Etoposide 54 (47-59) mg/kg	(129-140) 140mg/m2, or Busulfan 11.5 (9.8- 12.8) mg/kg and Cyclophosp hamide 120mg/kg

Konu ma 2022	Japan	Retrosp ective Cohort	333 (258 vs 75)	41 (16– 61) 52 (19– 69)*	NR	NR	0/0/333	TBI 8-12 Gy, Cyclophospha mide 120 mg/kg, highdose Cytosine Arabinoside (Ara-C) 12 g/m2	Busulfan 9.6 mg/kg, Fludarabine 180 mg/m2, high-dose Ara-C 12 g/m2, or Busulfan 12.8 mg/kg, Cyclophosp hamide 120 mg/kg, Fludarabine 100 mg/m2
Mora 2024	Spain	Retrosp ective Cohort	177 (114 vs 63)	31 (18– 53) vs 38 (18– 56)	138/3 9	101/76	13/164	TBI 12-13Gy + Cyclophospha mide 120mg/kg or TBI 12-13Gy + Fludarabine 120mg/m2	Thiotepa 10mg/kg, Busulfan 9.6mg/kg, Cyclophosp hamide 120mg/kg or Thiotepa 10mg/kg, Busulfan 9.6mg/kg, Fludarabine 120mg/m2
Mutsu hashi 2016	Japan	Retrosp ective Cohort	2130 (2028 vs 102)	39 (16- 68)*	NR	1771/3 59	1400/33 3/397	TBI≥8Gy + Cyclophospha mide 120mg/kg	Busulfan 16 mg/kg, Cyclophosp hamide 120 mg/kg, or Busulfan 12.8 mg/kg, Cyclophosp hamide 120 mg/kg
Niu 2022	Chin a	Retrosp ective Cohort	40 (23 vs 17)	28 (18- 46) vs 28.5 (18- 50)*	17/23	34/6	0/40/0	TBI 10Gy + Cyclophospha mide 50- 60mg/kg+ Etoposide 15 mg/kg	Busulfan 3.2 mg/Kg, Cyclophosp hamide 50- 60mg/Kg
Park 2019	Kore a	Retrosp ective	1562( 735 vs	39 (18-	NR	482/10 80	NR	Cyclophospha mide (524/735,	Busulfan or Fludarabine

		Cohort	827)	65) vs 41 (18- 65)*				71.2%), high-dose cytarabine (199/735, 27.1%), or melphalan (12/735, 1.6%)	and Busulfan
Pavlu 2019	Euro pe	Registry Study	2780 ( 2122 vs 658)	MRD +38 (18- 72, 28- 48), MRD- 36 (18- 70, 26-46)		2427/3 53	670/211 0/0	NR	NR
Sakella ri 2018		Retrosp ective Cohort	151 (84 vs 67)	29.4(1 7- 41.6) vs 29.1 (16.4- 41.8)	114/3 7	60/89	26/125/0	TBI 14.4Gy	Busulfan 4 mg/Kg
Shen 2024	Chin a	Retrosp ective Cohort	222( 83vs 139)	21 (4– 49) vs. 24 (2–52)	NR	117/ 105	NR	TBI plus Cyclophospha mide	busulfan plus cyclophosp hamide
Swobo da 2022	Euro pe	Retrosp ective Cohort	237(117v s119)	30.9 (18.1– 59.9) vs 35.8 (18.8– 61.7)	171/6 5	128/10 9	141/95	TBI >10 Gy plus Fludarabine	Thiotepa (two days, total dose of 10 mg/kg), Busulfan (three days, total dose of 9.6 mg/kg) and Fludarabine
Wang 2021	Taiw an	Retrosp ective Cohort	224 (83 vs 95)	28.1 (16.4- 56.3) vs 30.9 (15.5-	137/6 5	114/11 0	50/159/	TBI 150 centi- Gy and Cyclophospha mide 60 mg/kg/day	busulfan IV 3.2 mg/kg/day or oral 4 mg/kg/day PLUS

				52.3)*					cyclophosp hamide IV 60 mg/kg/ OR fludarabine 30 mg/m2/day , busulfan IV 3.2 mg/kg/day or oral 4 mg/kg/day and cyclophosp hamide IV 60 mg/kg/day
Zhang 2022	Chin a	Random ized Control Trial	545 ( 272 vs 273 )	27 (14- 61) vs 26 (14- 59)	NR	NR	NR	4.5 Gy/day plus cyclophospha mide 60 mg/kg once daily	Busulfan 3.2 mg/kg per day with cyclophosp hamide 60 mg/kg per day



	TBI	į	CHT	1	Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Abdeljelil 2024	32	61	14	34	4.3%	1.27 [0.80, 2.03]	
Bazarbachi 2020	18	60	4	55	1.5%	4.13 [1.49, 11.44]	97E
Cahu 2015	187	351	12	54	3.9%	2.40 [1.44, 3.99]	
Eroglu 2013	24	45	15	50	4.0%	1.78 [1.07, 2.94]	
Greil 2020	50	119	17	61	4.4%	1.51 [0.96, 2.38]	+ -
Harada 2019	171	355	79	152	7.6%	0.93 [0.77, 1.12]	-
Hirschbühl 2023	179	262	139	239	8.2%	1.17 [1.03, 1.35]	<del>  •</del>
Kebriaei 2018	434	819	170	299	8.4%	0.93 [0.83, 1.05]	+
Konuma 2022	206	258	37	75	7.0%	1.62 [1.28, 2.05]	
Mora 2024	52	114	28	63	5.7%	1.03 [0.73, 1.44]	<del> </del>
Mutsuhashi 2016	1399	2028	63	102	8.0%	1.12 [0.96, 1.30]	+
Niu 2022	19	23	6	17	2.8%	2.34 [1.20, 4.58]	
Pavlu 2019	1217	1816	588	964	8.8%	1.10 [1.03, 1.17]	+
Sakellari 2018	40	84	24	67	5.1%	1.33 [0.90, 1.97]	
Shen 2024	61	83	39	139	6.2%	2.62 [1.95, 3.52]	
Swoboda 2022	69	119	71	117	7.3%	0.96 [0.77, 1.18]	*
Wang 2021	32	83	22	141	4.3%	2.47 [1.54, 3.95]	N <del>a State</del>
Zhang 2022	19	23	6	17	2.8%	2.34 [1.20, 4.58]	A - 20 - 28
Total (95% CI)		6703		2646	100.0%	1.37 [1.20, 1.57]	•
Total events	4209		1334				
Heterogeneity: Tau <sup>2</sup> =	0.05; Chi	$i^2 = 100$	J.29, df=	17 (P <	0.00001	); I² = 83% —	0.1 0.2 0.5 1 2 5 10
Test for overall effect:	Z = 4.620	(P < 0.0	)0001)				Favours CHT Favours TBI

	TBI		CHT	- 2	Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Abdeljelil 2024	30	61	12	34	3.4%	1.39 [0.83, 2.35]	
Bazarbachi 2020	14	60	4	55	1.0%	3.21 [1.12, 9.16]	
Cahu 2015	174	351	10	54	2.9%	2.68 [1.51, 4.73]	S 123 S
Eroglu 2013	12	45	9	50	1.8%	1.48 [0.69, 3.18]	10 / 27-50 28
Greil 2020	48	119	15	61	3.7%	1.64 [1.00, 2.68]	<del>- 1</del>
Harada 2019	150	355	62	152	9.3%	1.04 [0.83, 1.30]	
Hirschbühl 2023	152	262	103	239	11.1%	1.35 [1.13, 1.61]	
Kebriaei 2018	393	819	135	299	12.4%	1.06 [0.92, 1.23]	+
Konuma 2022	167	258	27	75	6.7%	1.80 [1.31, 2.46]	
Mora 2024	48	114	25	63	5.5%	1.06 [0.73, 1.54]	N <del>a da</del>
Mutsuhashi 2016	1259	2028	52	102	10.5%	1.22 [1.00, 1.48]	
Niu 2022	17	23	9	17	3.5%	1.40 [0.84, 2.32]	× + 2 +
Sakellari 2018	39	84	24	67	5.1%	1.30 [0.87, 1.92]	<del>    •</del>
Shen 2024	49	83	64	139	8.4%	1.28 [0.99, 1.65]	
Swoboda 2022	62	119	59	117	8.6%	1.03 [0.81, 1.33]	9 <del>-  </del>
Wang 2021	18	83	27	141	3.3%	1.13 [0.67, 1.93]	
Zhang 2022	17	23	8	17	3.0%	1.57 [0.90, 2.75]	sala dina ak
Total (95% CI)		4887		1682	100.0%	1.28 [1.15, 1.43]	•
Total events	2649		645				
Heterogeneity: Tau <sup>2</sup> =	0.02; Ch	$i^2 = 29.$	08, df = 1	6 (P = 0)	$0.02$ ); $I^2 =$	45%	0.1 0.2 0.5 1 2 5 10
Test for overall effect:					38		0.1 0.2 0.5 1 2 5 10 Favours CHT Favours TBI